Text Size
47 studies found for:    Pertuzumab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Conditions: Neuroendocrine Carcinoma;   Neuroendocrine
Interventions: Drug: Bevacizumab;   Drug: Pertuzumab;   Drug: Sandostatin LAR® Depot
2 Active, not recruiting Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: pertuzumab;   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Other: immunohistochemistry staining method;   Other: fluorescence in situ hybridization;   Other: gene expression analysis;   Other: mutation analysis;   Other: polymerase chain reaction;   Other: laboratory biomarker analysis
3 Not yet recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
4 Active, not recruiting A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel
5 Recruiting Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
6 Not yet recruiting Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
Condition: Elderly Metastatic Breast Cancer Population
Interventions: Drug: Pertuzumab + trastuzumab;   Drug: Pertuzumab + trastuzumab + metronomic chemotherapy
7 Recruiting A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: pertuzumab [Perjeta];   Drug: placebo;   Drug: trastuzumab [Herceptin];   Drug: cisplatin;   Drug: capecitabine;   Drug: 5-fluorouracil
8 Recruiting A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: pertuzumab;   Drug: trastuzumab;   Drug: cisplatin;   Drug: capecitabine
9 Recruiting Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Condition: HER2-positive Metastatic Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: T-DM1
10 Active, not recruiting A Study of Perjeta (Pertuzumab) in Combination With Herceptin in Patients With Metastatic Breast Cancer.
Condition: Breast Cancer
Intervention: Drug: pertuzumab [Perjeta]
11 Not yet recruiting Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC)
Condition: Breast Cancer
Intervention: Other: 111In-Pertuzumab + SPECT-CT
12 Completed A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
Condition: Solid Cancers
Intervention: Drug: pertuzumab
13 Completed A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: rhuMAb 2C4 (pertuzumab)
14 Completed
Has Results 		Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Biological: pertuzumab;   Biological: Trastuzumab emtansine [Kadcyla]
15 Completed Safety and Efficacy Study of Omnitarg (Pertuzumab) to Treat Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: rhuMAb 2C4 (pertuzumab)
16 Completed
Has Results 		A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Pertuzumab;   Drug: Erlotinib
17 Terminated A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Adrenal Gland Tumors;   Neuroblastoma;   Pancreatic Neuroendocrine Tumors;   Multiple Endocrine Neoplasia
Interventions: Drug: pertuzumab;   Drug: erlotinib
18 Active, not recruiting A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel;   Drug: pertuzumab [Perjeta];   Drug: trastuzumab emtansine [Kadcyla]
19 Completed A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Pertuzumab (rhuMAb 2C4)
20 Terminated A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Condition: Pancreatic Cancer
Interventions: Drug: Pertuzumab;   Drug: Erlotinib
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years